Cancer Talk

News

Analysis of Key Breast Cancer Genes Reveals Distinct Profiles for African-American, European-American Women

Researchers have uncovered new information that may begin to explain why many African-American women are more likely to be diagnosed with aggressive, often deadly forms of breast cancer, which strengthens the evidence that increased dietary folate intake may prove to be an effective strategy for reducing risk for the disease in African-American women.
News

E-Cigs May be Harmful, Should be Regulated

A Roswell Park faculty member is co-author of a new policy statement from two major oncology organizations, the American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO), advocating for federal and state regulation of electronic cigarettes.

News

Nigerian Hematologist Receives Vital Training at Roswell Park

Thanks to a Visitor Training Program grant from the American Society of Hematology (ASH) awarded to Roswell Park hematopathlogist Vishala Neppalli, MD, visiting physician Tamunomieibi Wakama, MD, can now perform crucial pathology analyses, essential to accurate diagnosis and treatment of his pati

News

Overcoming Treatment Resistance in Prostate Cancer: Roswell Park Team Proposes a New Strategy

Researchers have discovered what may be a promising new approach for controlling aggressive, treatment-resistant forms of prostate cancer. Leigh Ellis, PhD, and colleagues at Roswell Park Cancer Institute (RPCI) have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen-targeted treatments enzalutamide and abiraterone acetate.
News

New Approach, New Hope: State Investment Will Fast-Track Innovative Roswell Park Research in Ovarian Cancer

Researchers at Roswell Park Cancer Institute have received a prestigious grant of nearly $12 million from the New York State Stem Cell Science Program to develop new therapies for advanced ovarian cancer. The four-year, $11.9 million grant to RPCI is one of three new state awards totaling $36 million to support innovative approaches for developing stem-cell based therapies for diseases that are notoriously hard to treat.